Matthew Judson is a research associate in the UNC Neuroscience Center at the University of North Carolina at Chapel Hill.
Matthew Judson
Research associate
University of North Carolina at Chapel Hill
From this contributor
Angelman syndrome: Bellwether for genetic therapy in autism
It is not a matter of whether there will be clinical trials of genetic therapy for Angelman syndrome, but when.
Angelman syndrome: Bellwether for genetic therapy in autism
By
Matthew Judson, Benjamin Philpot
16 October 2018 | 6 min read
Insights for autism from Angelman syndrome
Deletions or duplications of the UBE3A gene lead to both Angelman syndrome and some cases of autism, respectively. Studying the effects of altered gene dosage in this region will provide insights into brain defects and suggest targets for therapies for both disorders, says expert Benjamin Philpot.
Insights for autism from Angelman syndrome
By
Benjamin Philpot, Angela Mabb, Matthew Judson
19 July 2011 | 6 min read
Explore more from The Transmitter
Watching the mind build a world: Lucid dreaming as a model for generative perception
Lucid dreaming offers a rare opportunity to observe and probe perception from within.
Watching the mind build a world: Lucid dreaming as a model for generative perception
Lucid dreaming offers a rare opportunity to observe and probe perception from within.
By
Magdalena Paluchowska
13 July 2026 | 8 min read
From friend to foe: How the brain updates feelings toward others
A specific hippocampus-to-amygdala pathway reassigns emotional valence to a known individual, whereas the hippocampus’s own representation of that individual’s identity remains stable.
From friend to foe: How the brain updates feelings toward others
A specific hippocampus-to-amygdala pathway reassigns emotional valence to a known individual, whereas the hippocampus’s own representation of that individual’s identity remains stable.
By
Natalia Mesa
9 July 2026 | 5 min read
Mass-produced science is coming. What happens to scientists?
Artificial intelligence may soon enable researchers to generate high-quality science at a previously unimaginable speed. For science consumers—the public, medical patients, technology users—the likely effects will be positive. For scientists, the effects will be as disruptive as industrial mass production was for artisan manufacturers.
Mass-produced science is coming. What happens to scientists?
Artificial intelligence may soon enable researchers to generate high-quality science at a previously unimaginable speed. For science consumers—the public, medical patients, technology users—the likely effects will be positive. For scientists, the effects will be as disruptive as industrial mass production was for artisan manufacturers.
By
Kenneth Harris
9 July 2026 | 9 min read